

Special Issue

Cardiovascular Disease: Personalized Prevention, Management, and Treatment

Message from the Guest Editors

Cardiovascular disease (CVD) is the leading cause of death globally. Primary and secondary prevention of CVD risk is the most important part of clinical management. While evidence-based medicine is well-established, with clinical trial research integrated into practice guidelines and recommendations, there is growing recognition of the limitations of these data when it comes to individualized treatment decisions. Empirical evidence is still mostly reported by randomized controlled trials and meta-analyses as population-based hazard ratios and numbers-needed-to-treat (NNT), but they tend to indicate how to treat 'average' patients rather than specific individuals. With advances in personalized medicine, many treatments are now available for different subgroups with individualized treatment goals based on their characteristics and comorbidities, including cholesterol lowering, antiplatelet, and anticoagulant therapy. Personalized risk prediction models and individualized treatment effect predictions are the key points in the new era of precision personalized medicine.

Guest Editors

Dr. Gennaro Galasso

Dr. Marco Di Maio

Prof. Dr. Szu-Chia Chen

Deadline for manuscript submissions

closed (20 April 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/85735

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).